UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): February 20, 2007

NEUROCRINE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)		0-22705 (Commission File Number)		33-0525145 (IRS Employer Identification No.)

12790 El Camino Real (Address of principal executive offices)		92130 (Zip Code)

Registrant’s telephone number, including area code: (858) 617-7600

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

 

 

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS.

(b) On February 20, 2007, Neurocrine Biosciences, Inc. announced that Adrian Adams has resigned from the Company’s Board of Directors.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

99.1 Press release dated February 20, 2007.

SIGNATURES

     Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

EXHIBIT INDEX

Exhibit
Number				Document Description
	99.1			Press release dated February 20, 2007

EXHIBIT 99.1

FOR IMMEDIATE RELEASE:
Contact at Neurocrine Biosciences:
Elizabeth Foster
(858) 617-7600

NEUROCRINE BIOSCIENCES ANNOUNCES THE RESIGNATION OF
ADRIAN ADAMS FROM THE BOARD OF DIRECTORS

San Diego, CA, February 20, 2007 — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Adrian Adams has resigned from the Company’s Board of Directors.

“We are grateful to Adrian for the extensive experience that he has brought to Neurocrine over the past two years” said Joseph A. Mollica, Ph.D, Chairman of the Board, Neurocrine Biosciences.

“We want to thank Adrian for his hard work and dedication and for being such a valuable resource for Neurocrine,” said Gary A. Lyons, President and Chief Executive Officer of Neurocrine Biosciences.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, irritable bowel syndrome, endometriosis and CNS related disorders. Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the Internet at www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine’s business and finances in general. Other risks are described in the Company’s report on Form 10-K for the year ended December 31, 2006. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

# # #